Equities

Rafael Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RFL:NYQ

Rafael Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.20
  • Today's Change0.00 / 0.00%
  • Shares traded18.17k
  • 1 Year change-41.46%
  • Beta0.5874
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. The Company's segments include Healthcare, Infusion Technology and Real Estate. The Company’s lead candidate is Trappsol Cyclo, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder. The Healthcare segment comprises equity interests in LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., Cornerstone Pharmaceuticals, Inc., Cyclo, and Rafael Medical Devices, LLC. The Real Estate segment consists of the Company’s real estate holdings, which comprise a portion of one commercial building in Israel. The Infusion Technology segment comprises equity interests in Day Three Labs, Inc. LipoMedix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company.

  • Revenue in USD (TTM)1.03m
  • Net income in USD-31.33m
  • Incorporated2017
  • Employees21.00
  • Location
    Rafael Holdings Inc520 Broad StreetNEWARK 07120United StatesUSA
  • Phone+1 (212) 658-1450
  • Fax+1 (302) 636-5454
  • Websitehttps://rafaelholdings.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zhengye Biotechnology Holding Ltd22.25m-2.80m45.54m277.00--1.05134.802.05-0.059-0.0590.47870.91310.30991.622.0480,341.63-4.60---7.79--37.37---14.83--1.10-7.000.1902---11.95---64.04------
RADNOSTIX, INC.14.07m-231.26k48.72m41.00--11.89289.473.46-0.0004-0.00040.02680.00780.81475.968.18343,260.30-1.341.32-1.681.9559.8959.45-1.641.951.06-0.29280.59540.0013.319.19100.99--28.22--
Odonate Inc0.00-102.07m52.65m137.00--2,022.38-----108.70-108.700.0074.170.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
Janel Corp207.44m5.03m56.94m353.0011.502.216.620.27454.184.18172.0921.751.4732.804.14587,657.304.021.7613.355.3331.3326.692.730.96080.70133.100.39130.0013.2420.272,155.61---14.58--
Cumberland Pharmaceuticals, Inc.41.28m-3.33m58.03m91.00--2.2245.991.41-0.2331-0.23312.791.750.57881.723.80453,608.30-4.68-6.88-7.60-9.6584.4980.74-8.09-15.891.11-28.410.1688---4.261.95-3.19---29.32--
ImmuCell Corp27.77m2.32m59.70m70.0025.512.0011.892.150.25880.25883.093.290.61591.9011.42402,453.605.15-5.355.69-5.7740.9336.028.37-11.871.766.470.2415--51.6414.0662.65---19.66--
Rafael Holdings Inc1.03m-31.33m62.12m21.00--0.738--60.36-0.8471-0.84710.02841.630.0107--3.3549,000.00-32.33-45.03-37.62-51.7589.70---3,034.89-8,772.743.98--0.0074--43.96-28.5111.30---47.65--
LifeVantage Corp210.05m7.86m64.35m232.008.391.955.970.30640.59980.599816.162.583.242.4596.73905,370.7012.129.1718.9114.0878.7580.733.742.931.03--0.0035.0614.17-0.3794233.84-3.22-12.55--
MindWalk Holdings Corp14.98m-22.73m64.82m102.00--4.93--4.33-0.6315-0.61320.35110.28130.47456.674.50---72.01-32.32-90.53-36.4558.5055.79-151.78-100.974.09-23.680.17--0.008211.77-11.25--10.37--
Pelthos Therapeutics Inc7.41m-23.58m66.58m4.00--1.09--8.99-17.09-17.096.0218.850.1152----1,851,500.00-36.68---47.05--68.73---318.41--1.04-12.320.00-------7.78------
Pliant Therapeutics Inc0.00-175.50m68.21m171.00--0.3405-----2.87-2.870.003.260.00----0.00-48.60-38.70-52.81-41.26-------1,044.87----0.1319---100.00---30.35--31.90--
NovaBay Pharmaceuticals Inc2.83m-7.95m68.45m14.00------24.19-1.580.53770.5550.27180.7686--5.28202,142.90-215.92-61.58-404.37-83.7954.5659.49-280.92-77.39---91.560.0836---33.588.1948.52---20.59--
Nasus Pharma Ltd0.00-1.19m69.08m-----------0.1319-0.13830.00-0.47620.00-------373.32-----------------2.51---------54.23------
Scilex Holding Co40.36m-375.84m70.56m30.00------1.75-33.18-33.184.08-28.880.21457.271.85350,956.50-177.73------68.5975.06-828.56-176.540.0429-3.76----21.0721.8956.40---49.14--
Data as of Feb 13 2026. Currency figures normalised to Rafael Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

6.40%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 20251.28m2.52%
Geode Capital Management LLCas of 31 Dec 2025445.87k0.88%
IEQ Capital LLCas of 31 Dec 2025412.83k0.81%
BlackRock Fund Advisorsas of 31 Dec 2025323.70k0.64%
Dimensional Fund Advisors LPas of 31 Dec 2025268.70k0.53%
Vanguard Fiduciary Trust Co.as of 31 Dec 2025200.92k0.39%
Wells Fargo Clearing Services LLCas of 31 Dec 2025104.49k0.21%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 202584.48k0.17%
Citadel Securities LLCas of 30 Sep 202572.58k0.14%
Jane Street Capital LLCas of 31 Dec 202566.02k0.13%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.